rs6464926
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<i>EZH2</i> rs12670401 and rs6464926 polymorphisms, <i>EZH2</i> and <i>SMYD3</i> expression, clinical staging, lymph node metastasis, human epidermal growth factor receptor-2 (HER2) status, and metastasis may be correlated with breast cancer susceptibility and prognosis.
|
29089464 |
2018 |
rs664589
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<i>In vitro</i> and <i>in vivo</i> experiments showed that the rs664589 C to G mutation facilitated carcinogenesis and metastasis of colorectal cancer.
|
31311811 |
2019 |
rs1800470
|
|
|
0.020 |
GeneticVariation |
BEFREE |
<i>TGFB1</i> rs1800472 was positively, while rs1800470 was negatively associated with triple negativity, while rs1800470 positively correlated with menarche, but negatively with tumor size and molecular type, and rs1800469 correlated positively with menstrual irregularity, distant metastasis, nodal status, and hormonotherapy.
|
31405342 |
2019 |
rs1800469
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<i>TGFB1</i> rs1800472 was positively, while rs1800470 was negatively associated with triple negativity, while rs1800470 positively correlated with menarche, but negatively with tumor size and molecular type, and rs1800469 correlated positively with menstrual irregularity, distant metastasis, nodal status, and hormonotherapy.
|
31405342 |
2019 |
rs1799782
|
|
|
0.020 |
GeneticVariation |
BEFREE |
<i>XRCC1</i> rs1799782 may play an important role in the development and metastasis of breast cancer.
|
30568466 |
2018 |
rs767151455
|
|
|
0.010 |
GeneticVariation |
BEFREE |
<i>XRCC1</i> rs1799782 (C194T) polymorphism correlated with tumor metastasis and molecular subtypes in breast cancer.
|
30568466 |
2018 |
rs121434569
|
|
|
0.090 |
GeneticVariation |
BEFREE |
: Our results imply that blockade of the TGF-β signaling pathway combined with continuous EGFR TKI treatment will be beneficial in preventing metastasis in patients with EGFR TKI-resistant NSCLC without the EGFR T790M resistance mutation.
|
23334091 |
2013 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In malignant FNABs, BRAF(V600E) mutation was significantly associated with presence of extra-thyroidal extension and metastases after surgery.
|
21948220 |
2011 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
In malignant FNABs, BRAF(V600E) mutation was significantly associated with presence of extra-thyroidal extension and metastases after surgery.
|
21948220 |
2011 |
rs121913331
|
|
|
0.010 |
GeneticVariation |
BEFREE |
Arg1114X in APC gene, as a hot spot mutation in Chinese CRC, may predispose to the cancer metastasis of sporadic CRC.
|
17653897 |
2007 |
rs1049074086
|
|
|
0.010 |
GeneticVariation |
BEFREE |
S100P has been shown to mediate tumor growth, metastasis and invasion through the binding of Ca(2+) ions, receptor for advanced glycation end products, cytoskeletal protein ezrin, calcyclin-binding protein/Siah-1-interacting protein and cathepsin D. S100P could potentially serve as diagnostic marker, prognostic/predictive indicator and therapy target for different carcinomas.
|
21947242 |
2012 |
rs1284806277
|
|
|
0.030 |
GeneticVariation |
BEFREE |
S100P-derived RAGE antagonistic peptide reduces tumor growth and metastasis.
|
22718861 |
2012 |
rs1285136498
|
|
|
0.020 |
GeneticVariation |
BEFREE |
S100P - low molecular weight acidic protein has been shown to be involved in processes of proliferation, survival, angiogenesis, multidrug resistance and metastasis in various human malignancies.
|
23364898 |
2013 |
rs1284806277
|
|
|
0.030 |
GeneticVariation |
BEFREE |
S100P promoted the invasion and metastasis of CRC by activating RAGE/ERK signaling and promoting the epithelial-mesenchymal transition (EMT).
|
26975699 |
2016 |
rs13423759
|
|
|
0.010 |
GeneticVariation |
BEFREE |
rs13423759 allele C is significantly associated with the enhanced risk of breast cancer, elevated metastasis and HER2 positivity.
|
30336339 |
2018 |
rs351855
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A gly(388)arg polymorphism (rs351855) in the transmembrane domain of the fibroblast growth factor receptor (FGFR4) is associated with increased risk, staging, and metastasis in several different types of cancer.
|
22971346 |
2012 |
rs121434569
|
|
|
0.090 |
GeneticVariation |
BEFREE |
A concomitant squamous histology transformation in a lung non-T790M-resistant metastasis is also described.
|
24029120 |
2013 |
rs121909222
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A gene set enrichment analysis revealed increased expression of a metastasis pathway in Pten(∆):p53(R270H) vs. Pten(∆):p53(∆) spindle tumors.
|
26781438 |
2016 |
rs2227983
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A marked decrease on EGFR phosphorylation (P < 0.01) and c-Myc activation (P = 0.02) was observed in patients with R497K polymorphism, which is associated with decreased invasion (P = 0.01), lower nodal involvement (P = 0.02), reduced subsequent metastasis (P < 0.01), and longer disease-free (P < 0.01) as well as overall (P < 0.01) survival in stage II/III colorectal carcinoma patients who had received curative surgery.
|
17575224 |
2007 |
rs121434569
|
|
|
0.090 |
GeneticVariation |
BEFREE |
A mathematical model was established by combining a decision tree and the Markov approach to project the cost-effectiveness of osimertinib versus standard chemotherapy for the treatment of patients who harbor an EGFR T790M mutation and have disease progression after first-line EGFR TKI therapy with or without metastases to the central nervous system.
|
29101057 |
2018 |
rs200246209
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A significant correlation was observed for TIMP-2(303C>T) with higher pN stages (p = 0.01) and more distant metastasis (p = 0.02) for patients with the CC genotypes.
|
20730428 |
2010 |
rs172378
|
|
|
0.020 |
GeneticVariation |
BEFREE |
A synonymous single nucleotide polymorphism (SNP) rs172378 (A>G, Gly->Gly) in the complement component C1QA has been proposed to be associated with distant breast cancer metastasis.
|
20332777 |
2010 |
rs1800947
|
|
|
0.010 |
GeneticVariation |
BEFREE |
A trend for a younger age at diagnosis was found among the carriers of ACCCA (P=0.07) and the rs1800947 C-allele (P=0.06), as well as a trend for the latter to have more likely metastases (P=0.06), but not after Bonferroni correction (alpha=0.00208).
|
19436291 |
2009 |
rs113488022
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Additional analyses of multiple metastatic samples from individual patients using the highly sensitive MS-PCR without microdissection revealed that 5/19 (26%) patients had metastases that were discordant for the BRAF(V600E) mutation.
|
22235286 |
2012 |
rs121913377
|
|
|
0.100 |
GeneticVariation |
BEFREE |
Additional analyses of multiple metastatic samples from individual patients using the highly sensitive MS-PCR without microdissection revealed that 5/19 (26%) patients had metastases that were discordant for the BRAF(V600E) mutation.
|
22235286 |
2012 |